Table 1 The primary outcome
n | ||
|---|---|---|
KQ 1 | Does rebiopsy in the 1st or 2nd generation EGFR-TKI refractory patients improve prognosis? | 1 |
KQ 2 | What are the rebiopsy samples? | 98 |
KQ 3 | How are EGFR gene mutations detected? | 93 |
KQ 4 | Is the benefit of liquid biopsy greater than the harm? | 1 |
KQ 4’ | Is the benefit of tissue rebiopsy greater than the harm? | 8 |
KQ 5 | How often is T790M mutation detected in the 1st or 2nd generation EGFR-TKI refractory cases? | 99 |
KQ 6 | How is the prognosis when the 3rd generation EGFR- TKI is administered to T790M positive cases? | 11 |
KQ 7 | Is the benefit of the 3rd generation EGFR-TKI to T790M positive cases greater than the harm? | 1 |
KQ 8 | How is the prognosis of T790M negative cases? | 29 |
KQ 9 | How is the prognosis when rebiopsy is not performed in the 1st or 2nd generation EGFR-TKI refractory cases? | 1 |